Takeda to acquire Maverick Therapeutics

By The Science Advisory Board staff writers

March 9, 2021 -- Takeda Pharmaceutical has exercised its option to purchase T cell-targeted immunotherapy developer Maverick Therapeutics for up to $525 million in upfront and potential milestone payments.

Culminating a collaboration that began in 2017, the acquisition expands Takeda's immuno-oncology portfolio with Maverick's Cobra T-cell engager platform as well as two development candidates for treating solid tumors, according to the vendor. Maverick's lead candidate TAK-186 (formerly known as MVC-101) is a conditionally active T-cell engager that's currently being evaluated in a phase I/II study for the treatment of epidermal growth factor receptor (EGFR)-expressing solid tumors.

In addition, Maverick's AK-280 candidate -- formerly known as MVC-280 -- is expected to enter the clinic in the second half of Takeda's fiscal 2021 for the treatment of patients with B7H3-expressing solid tumors, according to the company. Upon expected closure of the deal in the first quarter of Takeda's fiscal year, Maverick employees, including its team of scientists, will join Takeda's research and development organization.

Startup Ensoma launches with gene therapy vector platform
A new genomic medicine startup called Ensoma made its corporate debut this week, raising $70 million in financing and entering into a strategic collaboration...
Evozyne to develop synthetic proteins for Takeda gene therapies
Molecular engineering company Evozyne has signed a strategic collaboration and license agreement with Takeda Pharmaceutical. The partnership's aim is...
Top biopharma companies form data exchange nonprofit
Ten of the world's largest biopharmaceutical companies publicly launched a new nonprofit corporation, Accumulus Synergy. The aim is to support interactions...
KSQ Therapeutics, Takeda to develop novel cancer immunotherapies
KSQ Therapeutics has entered into a broad strategic collaboration with Takeda Pharmaceutical to research, develop, and commercialize novel immune-based...
Takeda to distribute Y-mAbs' cancer antibody treatment in Israel
Y-mAbs and Takeda Israel, a subsidiary of Takeda Pharmaceutical, have entered into an exclusive license and distribution agreement for the registration...

Copyright © 2021 scienceboard.net

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter